WO2000004889A1 - Use of glucose uptake enhancer for reducing post-ischemic injury of the heart - Google Patents

Use of glucose uptake enhancer for reducing post-ischemic injury of the heart Download PDF

Info

Publication number
WO2000004889A1
WO2000004889A1 PCT/GB1999/002358 GB9902358W WO0004889A1 WO 2000004889 A1 WO2000004889 A1 WO 2000004889A1 GB 9902358 W GB9902358 W GB 9902358W WO 0004889 A1 WO0004889 A1 WO 0004889A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically acceptable
glucose uptake
heart
compound
uptake enhancer
Prior art date
Application number
PCT/GB1999/002358
Other languages
French (fr)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Laboratoires Pharmaceutiques
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority to EA200100164A priority Critical patent/EA004772B1/en
Priority to CA002338216A priority patent/CA2338216A1/en
Priority to PL99345663A priority patent/PL345663A1/en
Priority to AU50535/99A priority patent/AU5053599A/en
Priority to SI9930889T priority patent/SI1098638T1/en
Priority to EP99934911A priority patent/EP1098638B1/en
Priority to BR9912144-1A priority patent/BR9912144A/en
Priority to NZ509175A priority patent/NZ509175A/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Laboratoires Pharmaceutiques filed Critical Smithkline Beecham Plc
Priority to DE69930125T priority patent/DE69930125T2/en
Priority to KR1020017000924A priority patent/KR20010079550A/en
Priority to IL14074199A priority patent/IL140741A0/en
Priority to JP2000560882A priority patent/JP2002521325A/en
Priority to APAP/P/2001/002033A priority patent/AP1416A/en
Priority to SK102-2001A priority patent/SK1022001A3/en
Publication of WO2000004889A1 publication Critical patent/WO2000004889A1/en
Priority to NO20010293A priority patent/NO20010293L/en
Priority to BG105251A priority patent/BG105251A/en
Priority to CY20061100616T priority patent/CY1106078T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to a novel method for preventing or reducing post- ischaemic injury of the heart, in particular myocardial infarction or for improving the functional recovery of the heart following myocardial ischaemia.
  • Cardiovascular disease is a leading cause of mortality in adult diabetics of both Type 1 and Type 2 etiologies.
  • the underlying presence of cardiovascular disease in diabetes means not only that the likely incidence of myocardial infarction is higher in the diabetic population but that its occurrence carries a substantially greater risk of mortality for diabetics than non-diabetics.
  • European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and anti- hyperlipidaemic activity.
  • thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4-dione (hereinafter 'Compound (I)').
  • WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.
  • Compound (I) is an example of a class of anti-hyperglycaemic agents known as 'insulin sensitisers'.
  • Compound (I) is a thiazolidinedione insulin sensitiser.
  • Thiazolidinedione insulin sensitisers include compounds comprising a 2,4-thiazolidinedione moiety.
  • Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers WO93/21166 and WO94/01420. These compounds are herein referred to as 'acyclic insulin sensitisers'.
  • Other examples of acyclic insulin sensitisers are those disclosed in United States Patent Number 5232945 and International Patent Applications, Publication Numbers WO92/03425 and WO91/19702.
  • Examples of other insulin sensitisers are those disclosed in European Patent Application, Publication Number 0533933, Japanese Patent Application Publication Number 05271204 and United States Patent Number 5264451.
  • Compound (I) exerts a cardioprotective effect on the diabetic heart and is therefore effective at preventing or reducing post-ischaemic injury, such as myocardial infarction.
  • the acute administration of Compound (I) is also indicated to improve the functional recovery of the diabetic heart following myocardial ischaemia.
  • the present invention provides a method for reducing post-ischaemic injury of the heart, in particular myocardial infarction, which method comprises administration, especially acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
  • the invention also provides a method for improving the functional recovery of the heart following myocardial ischaemia which method comprises administration, especially acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
  • the invention provides a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use in reducing post-ischaemic injury of the heart, in particular myocardial infarction or for use in improving the functional recovery of the heart following myocardial ischaemia .
  • a glucose uptake enhancer such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use in reducing post-ischaemic injury of the heart, in particular myocardial infarction or for use in improving the functional recovery of the heart following myocardial ischaemia .
  • the human or non-human mammals may be suffering from diabetes mellitus or a related disorder.
  • the diabetes mellitus is Type 1 diabetes mellitus.
  • the diabetes mellitus is Type 2 diabetes mellitus.
  • a suitable glucose uptake enhancer is an insulin sensitiser.
  • a suitable glucose uptake enhancer is a thiazolidinedione.
  • Suitable thiazolidinediones are those disclosed in the above mentioned publications.
  • a preferred thiazolidinedione is Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof.
  • thiazolidinediones include (+) -5-[[4-[(3,4-dihydro-6- hydroxy-2, 5, 7, 8-tetramethyl-2H-l-benzopyran-2-yl)methoxy]phenyl]methyl]- 2,4-thiazolidinedione (or troglitazone), 5-[4-[(l- methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4- [2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable derivative thereof.
  • a suitable pharmaceutically acceptable derivative is a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate, including a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.
  • Suitable pharmaceutically acceptable derivatives, including pharmaceutically acceptable salts and pharmaceutically acceptable solvates, of the glucose uptake enhancer, for example the thiazolidinediones, are as described in the above mentioned publications and standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press).
  • Suitable pharmaceutically acceptable salts of Compound (I) include those described in EP 0306228 and WO94/05659.
  • a preferred pharmaceutically acceptable salt is a maleate.
  • Suitable pharmaceutically acceptable solvated forms of Compound (I) include those described in EP 0306228 and WO94/05659, in particular hydrates.
  • glucose uptake enhancers such as the thiazolidinediones, for example Compound (I)
  • thiazolidinediones for example Compound (I)
  • Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the method of the invention, either as individual tautomeric forms or as mixtures thereof.
  • glucose uptake enhancers such as the thiazolidinediones, for example Compound (I)
  • the glucose uptake enhancers such as the thiazolidinediones, including the pharmaceutically acceptable derivatives thereof, are prepared using conventional methods; for example the thiazolidinediones are conveniently prepared according to the methods disclosed in the above mentioned publications:
  • Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, such as a salt thereof or a pharmaceutically acceptable solvate thereof, may be prepared using the processes described in EP 0306228 and WO94/05659.
  • stereoisomeric forms such as those of the thiazolidinediones, may be prepared and separated as required, according to known methods such as those disclosed in the above mentioned publications.
  • the above-mentioned feature of the acute administration of glucose uptake enhancer, especially of the thiazolidinediones such as Compound (I), is considered to comprise in its own right a further part of the present invention. Accordingly, the invention further provides a glucose uptake enhancer, such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use as an acutely administerable therapeutic substance.
  • a glucose uptake enhancer such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof
  • the present invention also provides a glucose uptake enhancer, such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use as an acutely administrable cardioprotective agent, especially for preventing or reducing post- ischaemic injury of the heart, in particular myocardial infarction,
  • a glucose uptake enhancer such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof
  • the present invention also provides a glucose uptake enhancer, such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for acute administration for improving the functional recovery of the heart following myocardial ischaemia.
  • a glucose uptake enhancer such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof
  • the glucose uptake enhancer such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier wherein such composition is adapted for acute administration.
  • the present invention provides a pharmaceutical composition for use as an acutely administerable cardioprotective agent, especially for preventing or reducing post-ischaemic injury of the heart, in particular myocardial infarction, which composition comprises a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • a glucose uptake enhancer such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • the invention further provides a pharmaceutical composition for acute administration for improving the functional recovery of the heart following myocardial ischaemia, which composition comprises a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • a glucose uptake enhancer such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
  • the invention further provides a method for enhancing recovery after surgery, especially major surgery, for example cardiac surgery, which method comprises administration, generally acute administration, of an effective, non- toxic amount of a glucose uptake enhancer such as Compound (I), or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof.
  • a glucose uptake enhancer such as Compound (I)
  • Said administration of the glucose uptake enhancer may be before or after surgery.
  • Particular patient groups include the elderly such as post-60 year age groups.
  • pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
  • post-ischaemic injury of the heart includes myocardial infarction and certain arrhythmias, especially due to myocardial infarction.
  • improving the functional recovery of the heart includes improving or restoring cardiac output and/or enhancing the recovery, especially the rate of recovery, of cardiac output.
  • acute administration or phrases or terms used to convey an equivalent meaning to acute administration refer to a single administration of the medicament or the short term use.
  • Short term use of a thiazolidinedione insulin sensitiser means a period of time less than that associated with an antihyperglycaemic effect.
  • a suitable short term use period is 3-4 weeks.
  • glucose uptake enhancer means an agent which increases basal (insulin independent) or insulin-stimulated uptake of glucose into a cell.
  • the active medicaments are preferably administered in pharmaceutical composition form.
  • compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.
  • compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • composition of the invention is in the form of a unit dose.
  • Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
  • binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
  • fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
  • tabletting lubricants for example magnesium stearate
  • disintegrants for example star
  • compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
  • Suitable dosage regimens including details of unit dosages, for the thiazolidinediones include those described in the above mentioned publications or in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press).
  • the glucose uptake enhancer such as Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, is generally administered as a single dose.
  • additional doses may be administered to provide suitable short-term, non-chronic treatments, for example to prevent or reduce post- ischaemic injury, such as myocardial infarction, due to a subsequent ischaemic event and/or to prevent or reduce the severity of such an event and/or its reoccurrence.
  • dosages are envisaged to include higher doses than those associated with an anti-hyperglycaemic effect.
  • the treatment comprises the sequential administration or the co-administration of a thrombolytic agent, such as streptokinase, with the glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof.
  • a thrombolytic agent such as streptokinase
  • the glucose uptake enhancer such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof.
  • the invention also comprises a pharmaceutical composition
  • a pharmaceutical composition comprising a glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, and a thrombolytic agent, such as streptokinase, and a pharmaceutically acceptable carrier.
  • a glucose uptake enhancer such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof
  • a thrombolytic agent such as streptokinase
  • the particular thrombolytic agent and its required dosage include those described in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press).
  • the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose,
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, a preservative and buffering agent can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the active compound may be suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
  • compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
  • the cardioprotective effects, especially the acute cardioprotective effects, of a glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof are also considered to provide potential for use as a cardioplegic agent.
  • the present invention also provides a glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof for use as a cardioplegic agent, especially in cardioplegic solutions, to preserve cardiac function during surgery.
  • a cardioplegic agent includes use in cardiac by-pass surgery.
  • Particular uses of a cardioplegic agent include use in cardiac transplant surgery for maintaining cardiac viability.
  • cardioplegic solutions of Compound (I) are envisaged to contain between 0.0 l ⁇ M and 10 ⁇ M of Compound (I).
  • the invention also provides a pharmaceutical composition, adapted for use as a cardioplegic agent, which comprises a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier.
  • a glucose uptake enhancer such as Compound (I) or a tautomeric form thereof, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier.
  • compositions are prepared and formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press and Harry's Cosmeticology (Leonard Hill Books) or the above mentioned publications.
  • cardioprotective effects of the invention may be identified by using test methods such as those provided hereinafter or those known in the art such as those disclosed in Khandoudi N, Bernard M, Cozzone P, Feuvray D (Intracellular pH and role of Na+/H+ exchange during ischaemia and reperfusion of normal and diabetic rat hearts. Cardiovasc Res 24: 873-878, 1990) or in Khandoudi N, Laville MP, Bril A (Protective effect of the Sodium/Hydrogen exchange inhibitors during global low flow-ischemia. J Cardiovasc Pharmacol 28: 540-546, 1996).
  • Table 1 shows baseline ventricular function of isolated working hearts from male Wistar rats: with vehicle or Compound (I) added to the perfusate pre- ischaemia;
  • Table 2 shows baseline ventricular function of isolated working hearts from STZ-diabetic rats: with vehicle or Compound (I) added to the perfusate pre- iscaemia;
  • Figure 1 shows the effect of Compound (I) on post-ischaemic functional impairment of normal Male Wistar rat working hearts
  • Figure 2 shows the effect of Compound (I) on post-ischaemic functional impairment of STZ-diabetic male Wistar rat working hearts.
  • Test Systems Male Wistar rats (Charles River; St Aubin les Elbeuf, France), with a body weight ranging from 260 to 280g were housed on a 12h/12h light-dark cycle with access to water and standard rat chow ad libitum. An acclimatisation period of at least one week was allowed prior to experiment.
  • Induction of experimental diabetes Male Wistar rats weighing between 300 and 320 g were fasted overnight and made diabetic by a single intravenous injection of STZ, 40 mg/kg body weight. The development of diabetes and its persistence were monitored by serial quantitative measurements of glucose in the urine with reagent strips. On the day of the experiment, the severity of diabetes was assessed by measuring glucose concentrations from blood samples collected at the time of heart excision. Only rats with plasma glucose levels exceeding 20 mM were considered diabetic and included in these experiments.
  • Rats were anaesthetized using thiopental sodium (50 mg/kg body weight intraperitoneally). Hearts from normoglycaemic and one-month STZ- induced diabetic rats, were quickly removed and immersed in ice-cold buffer to produce an immediate cessation of contractility. The aorta was dissected free and then mounted onto a cannula attached to a perfusion apparatus. Retrograde perfusion of the heart was started for 10 min by the Langendorff method and then switched to perfusion using the working-heart technique [16]. The perfusion fluid was Krebs-Henseleit buffer (pH 7.4) of the following composition (mM): NaCl 118, NaHCO 23, KC1 4.7, KH2PO4 1.2, MgCl 2
  • Induction of global ischaemia and re-perfusion Total ischaemia was initiated by clamping the left atrium and the aortic perfusion tubes and reducing coronary flow to zero for 30 minutes. The hearts were then re-perfused at 37°C in working heart mode and recovery of ventricular function was followed for 30 minutes.
  • this agent was added to the perfusate 15-min prior to the induction of ischaemia and then maintained throughout the re-perfusion phase.
  • FIG. 1 The data demonstrate that recovery of post-ischaemic control hearts is relatively slow and not all functional parameters (e.g. cardiac output) return to pre-ischaemic levels, even after 30 min re-perfusion.
  • Inclusion of Compound (I) in the perfusate prior to ischaemia significantly enhanced the rate of recovery of each of the functional indices.
  • inclusion of Compound (I) (1 ⁇ M) in the perfusate for 15 min prior to, during ischaemia and during the subsequent re-perfusion phase enhanced the recovery in cardiac output and heart rate.
  • Troglitazone reduces contraction by inhibiton of vascular smooth muscle cell Ca 2+ currents and not endothelial nitric oxide production. Diabetes, 46, 659-664.
  • BRL-049653/RSD-100T6C/1 Differential effects of insulin-sensitizing agents troglitazone and rosiglitazone (BRL 49653) on Ca 2+ and K+ currents in rat vascular smooth muscle cells. Knock, G.A., Mishra, S.K. & Aaronson, P.I.. June 1998.
  • Troglitazone inhibits type 2 K ATP channel activity and depolarises tolbutamide-sensitive neurones in the rat ventromedial hypothalamus.
  • troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes, 43, 447-453.
  • Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes, 45, 1822-1825.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.

Description

GLUCOSE UPTAKE ENHANCER FOR REDUCING POST-ISCHEMIC INJURY OF THE HEART
This invention relates to a novel method for preventing or reducing post- ischaemic injury of the heart, in particular myocardial infarction or for improving the functional recovery of the heart following myocardial ischaemia.
Cardiovascular disease is a leading cause of mortality in adult diabetics of both Type 1 and Type 2 etiologies. The underlying presence of cardiovascular disease in diabetes means not only that the likely incidence of myocardial infarction is higher in the diabetic population but that its occurrence carries a substantially greater risk of mortality for diabetics than non-diabetics. European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and anti- hyperlipidaemic activity. One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4-dione (hereinafter 'Compound (I)'). WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.
Compound (I) is an example of a class of anti-hyperglycaemic agents known as 'insulin sensitisers'. In particular Compound (I) is a thiazolidinedione insulin sensitiser. Thiazolidinedione insulin sensitisers include compounds comprising a 2,4-thiazolidinedione moiety.
European Patent Applications, Publication Numbers: 0008203, 0139421, 0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0193256, 0319189, 0332331, 0332332, 0528734, 0508740; International Patent Application, Publication Numbers 92/18501, 93/02079, 93/22445 and United States Patent Numbers 4687777, 5104888 and 5478852, also disclose certain thiazolidinedione insulin sensitisers.
Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers WO93/21166 and WO94/01420. These compounds are herein referred to as 'acyclic insulin sensitisers'. Other examples of acyclic insulin sensitisers are those disclosed in United States Patent Number 5232945 and International Patent Applications, Publication Numbers WO92/03425 and WO91/19702. Examples of other insulin sensitisers are those disclosed in European Patent Application, Publication Number 0533933, Japanese Patent Application Publication Number 05271204 and United States Patent Number 5264451.
The above mentioned publications are incorporated herein by reference.
It is suggested by Shimabukuro et al (Diabetes 44[Suppl 1]:797 (Abstract) 1995) that long term treatment with the thiazolidinedione, troglitazone, preserves cardiac function of the diabetic heart. Also, Eckel et al (Diabetes, 46 [Suppl 1]: 575 (Abstract) 1997) have suggested that chronic exposure to troglitazone may exert a cardioprotective effect by increasing glucose supply to the myocytes of the diabetic heart.
It is now surprisingly indicated that the acute administration of Compound (I) exerts a cardioprotective effect on the diabetic heart and is therefore effective at preventing or reducing post-ischaemic injury, such as myocardial infarction. The acute administration of Compound (I) is also indicated to improve the functional recovery of the diabetic heart following myocardial ischaemia.
In addition, and perhaps more surprisingly, it is indicated that administration, especially acute administration, of Compound (I) exerts a particularly effective cardioprotective effect on the non-diabetic heart.
Accordingly, the present invention provides a method for reducing post-ischaemic injury of the heart, in particular myocardial infarction, which method comprises administration, especially acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
The invention also provides a method for improving the functional recovery of the heart following myocardial ischaemia which method comprises administration, especially acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
In one particular aspect the invention provides a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use in reducing post-ischaemic injury of the heart, in particular myocardial infarction or for use in improving the functional recovery of the heart following myocardial ischaemia .
Certain of the human or non-human mammals may be suffering from diabetes mellitus or a related disorder. Particularly, the diabetes mellitus is Type 1 diabetes mellitus. Particularly, the diabetes mellitus is Type 2 diabetes mellitus.
-?- A suitable glucose uptake enhancer is an insulin sensitiser.
A suitable glucose uptake enhancer is a thiazolidinedione.
Suitable thiazolidinediones are those disclosed in the above mentioned publications.
A preferred thiazolidinedione is Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof.
Other suitable thiazolidinediones include (+) -5-[[4-[(3,4-dihydro-6- hydroxy-2, 5, 7, 8-tetramethyl-2H-l-benzopyran-2-yl)methoxy]phenyl]methyl]- 2,4-thiazolidinedione (or troglitazone), 5-[4-[(l- methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4- [2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable derivative thereof.
A suitable pharmaceutically acceptable derivative is a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate, including a pharmaceutically acceptable solvate of a pharmaceutically acceptable salt.
Suitable pharmaceutically acceptable derivatives, including pharmaceutically acceptable salts and pharmaceutically acceptable solvates, of the glucose uptake enhancer, for example the thiazolidinediones, are as described in the above mentioned publications and standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press).
Suitable pharmaceutically acceptable salts of Compound (I) include those described in EP 0306228 and WO94/05659. A preferred pharmaceutically acceptable salt is a maleate.
Suitable pharmaceutically acceptable solvated forms of Compound (I) include those described in EP 0306228 and WO94/05659, in particular hydrates.
Certain of the glucose uptake enhancers, such as the thiazolidinediones, for example Compound (I), may exist in one of several tautomeric forms, all of which are encompassed by the method of the invention, either as individual tautomeric forms or as mixtures thereof.
Certain of the glucose uptake enhancers, such as the thiazolidinediones, for example Compound (I), may also contain chiral carbon atoms, and hence can exist in several stereoisomeric forms, all of which are encompassed by the method of the invention whether as individual isomers or as mixtures of isomers.
- The glucose uptake enhancers, such as the thiazolidinediones, including the pharmaceutically acceptable derivatives thereof, are prepared using conventional methods; for example the thiazolidinediones are conveniently prepared according to the methods disclosed in the above mentioned publications: Thus Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, such as a salt thereof or a pharmaceutically acceptable solvate thereof, may be prepared using the processes described in EP 0306228 and WO94/05659.
The above mentioned stereoisomeric forms, such as those of the thiazolidinediones, may be prepared and separated as required, according to known methods such as those disclosed in the above mentioned publications.
The above-mentioned feature of the acute administration of glucose uptake enhancer, especially of the thiazolidinediones such as Compound (I), is considered to comprise in its own right a further part of the present invention. Accordingly, the invention further provides a glucose uptake enhancer, such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use as an acutely administerable therapeutic substance.
The present invention also provides a glucose uptake enhancer, such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for use as an acutely administrable cardioprotective agent, especially for preventing or reducing post- ischaemic injury of the heart, in particular myocardial infarction,
The present invention also provides a glucose uptake enhancer, such as a thiazolidinedione for example Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, for acute administration for improving the functional recovery of the heart following myocardial ischaemia.
In all of the above-mentioned treatments, the glucose uptake enhancer such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
Accordingly, the present invention also provides a pharmaceutical composition comprising a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier wherein such composition is adapted for acute administration.
More particularly, the present invention provides a pharmaceutical composition for use as an acutely administerable cardioprotective agent, especially for preventing or reducing post-ischaemic injury of the heart, in particular myocardial infarction, which composition comprises a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
The invention further provides a pharmaceutical composition for acute administration for improving the functional recovery of the heart following myocardial ischaemia, which composition comprises a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
It is also envisaged that the acute cardioprotective effect of a glucose uptake enhancer would be useful for enhancing post-surgical recovery. Accordingly, the invention further provides a method for enhancing recovery after surgery, especially major surgery, for example cardiac surgery, which method comprises administration, generally acute administration, of an effective, non- toxic amount of a glucose uptake enhancer such as Compound (I), or a tautomeric form thereof or a pharmaceutically acceptable derivative thereof. Said administration of the glucose uptake enhancer may be before or after surgery. Particular patient groups include the elderly such as post-60 year age groups.
As used herein the term "pharmaceutically acceptable" embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
As used herein "post-ischaemic injury of the heart" includes myocardial infarction and certain arrhythmias, especially due to myocardial infarction.
As used herein "improving the functional recovery of the heart" includes improving or restoring cardiac output and/or enhancing the recovery, especially the rate of recovery, of cardiac output.
As used herein "acute administration" or phrases or terms used to convey an equivalent meaning to acute administration refer to a single administration of the medicament or the short term use. Short term use of a thiazolidinedione insulin sensitiser means a period of time less than that associated with an antihyperglycaemic effect. A suitable short term use period is 3-4 weeks.
As used herein "glucose uptake enhancer" means an agent which increases basal (insulin independent) or insulin-stimulated uptake of glucose into a cell..
In the method of the invention, the active medicaments are preferably administered in pharmaceutical composition form.
Usually the compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.
The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.
Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
The compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
Suitable dosage regimens, including details of unit dosages, for the thiazolidinediones include those described in the above mentioned publications or in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press).
The compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosages. For example, for compound (I), unit doses suitably contain up to 12 mg of Compound (I).
In the acute treatment of the invention, the glucose uptake enhancer, such as Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, is generally administered as a single dose. However, if required, additional doses may be administered to provide suitable short-term, non-chronic treatments, for example to prevent or reduce post- ischaemic injury, such as myocardial infarction, due to a subsequent ischaemic event and/or to prevent or reduce the severity of such an event and/or its reoccurrence.
In the above mentioned acute administration of glucose uptake enhancers, for example thiazolidinediones, dosages are envisaged to include higher doses than those associated with an anti-hyperglycaemic effect.
In a further aspect the treatment comprises the sequential administration or the co-administration of a thrombolytic agent, such as streptokinase, with the glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof.
Accordingly, the invention also comprises a pharmaceutical composition comprising a glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, and a thrombolytic agent, such as streptokinase, and a pharmaceutically acceptable carrier.
The particular thrombolytic agent and its required dosage include those described in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press). The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agent can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the active compound may be suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
Finally, the cardioprotective effects, especially the acute cardioprotective effects, of a glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof, are also considered to provide potential for use as a cardioplegic agent. Accordingly, the present invention also provides a glucose uptake enhancer, such as Compound (I) or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof for use as a cardioplegic agent, especially in cardioplegic solutions, to preserve cardiac function during surgery.
Particular uses of a cardioplegic agent include use in cardiac by-pass surgery. Particular uses of a cardioplegic agent include use in cardiac transplant surgery for maintaining cardiac viability.
The amount of active agent required for cardioplegic use will be provided by standard tests methods such as those described herein, for example cardioplegic solutions of Compound (I) are envisaged to contain between 0.0 lμM and 10 μM of Compound (I).
In a further aspect, the invention also provides a pharmaceutical composition, adapted for use as a cardioplegic agent, which comprises a glucose uptake enhancer, such as Compound (I) or a tautomeric form thereof, or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier.
The compositions are prepared and formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press and Harry's Cosmeticology (Leonard Hill Books) or the above mentioned publications.
The cardioprotective effects of the invention may be identified by using test methods such as those provided hereinafter or those known in the art such as those disclosed in Khandoudi N, Bernard M, Cozzone P, Feuvray D (Intracellular pH and role of Na+/H+ exchange during ischaemia and reperfusion of normal and diabetic rat hearts. Cardiovasc Res 24: 873-878, 1990) or in Khandoudi N, Laville MP, Bril A (Protective effect of the Sodium/Hydrogen exchange inhibitors during global low flow-ischemia. J Cardiovasc Pharmacol 28: 540-546, 1996).
No adverse toxicological effects have been established for the compositions or methods of the invention in the above mentioned dosage ranges.
In the Tables and Figures shown below:
Table 1 : shows baseline ventricular function of isolated working hearts from male Wistar rats: with vehicle or Compound (I) added to the perfusate pre- ischaemia;
Table 2: shows baseline ventricular function of isolated working hearts from STZ-diabetic rats: with vehicle or Compound (I) added to the perfusate pre- iscaemia;
Figure 1 : shows the effect of Compound (I) on post-ischaemic functional impairment of normal Male Wistar rat working hearts; and
Figure 2: shows the effect of Compound (I) on post-ischaemic functional impairment of STZ-diabetic male Wistar rat working hearts.
The following example illustrates the invention but does not limit it in any way MATERIALS & METHODS ~~
Materials: Stock solutions of Compound (I) were prepared freshly in dimethylsulphoxide (DMSO) and further dilutions were made in the perfusion buffer. The maximum vehicle DMSO concentration was 0.001% which was without effect on any parameters when added by itself in control experiments.
A solution of streptozotocin (STZ commercially available) was prepared in citrate buffer (40 mg/ml).
Test Systems: Male Wistar rats (Charles River; St Aubin les Elbeuf, France), with a body weight ranging from 260 to 280g were housed on a 12h/12h light-dark cycle with access to water and standard rat chow ad libitum. An acclimatisation period of at least one week was allowed prior to experiment.
Induction of experimental diabetes: Male Wistar rats weighing between 300 and 320 g were fasted overnight and made diabetic by a single intravenous injection of STZ, 40 mg/kg body weight. The development of diabetes and its persistence were monitored by serial quantitative measurements of glucose in the urine with reagent strips. On the day of the experiment, the severity of diabetes was assessed by measuring glucose concentrations from blood samples collected at the time of heart excision. Only rats with plasma glucose levels exceeding 20 mM were considered diabetic and included in these experiments.
Experimental Procedures
Perfusion of isolated hearts: Rats were anaesthetized using thiopental sodium (50 mg/kg body weight intraperitoneally). Hearts from normoglycaemic and one-month STZ- induced diabetic rats, were quickly removed and immersed in ice-cold buffer to produce an immediate cessation of contractility. The aorta was dissected free and then mounted onto a cannula attached to a perfusion apparatus. Retrograde perfusion of the heart was started for 10 min by the Langendorff method and then switched to perfusion using the working-heart technique [16]. The perfusion fluid was Krebs-Henseleit buffer (pH 7.4) of the following composition (mM): NaCl 118, NaHCO 23, KC1 4.7, KH2PO4 1.2, MgCl2
1.2, CaCl2 1-25, glucose 11, pyruvate 2. The buffer was continuously gassed with a 95%O2/5%CO2 mixture and the entire system was thermoregulated at 37°C. The perfusate was not recirculated. Preload was held at a pressure of 15 cm H2O and afterload, as well as coronary perfusion pressure, were kept constant at 80 cm H2O.
Measurement of cardiac function: Both heart rate (beat/min) and peak systolic pressure (mm Hg) were monitored continuously via the fluid-filled side-arm on the aortic cannula connected to a pressure transducer (Statham P23Db) and recorded on a Gould pen-recorder (model 8188.602). Aortic and coronary flows (ml/min) were measured by timed collection. Cardiac output (ml/min) was derived from the sum of the aortic and coronary flows. Stroke volume (ml/beat) was derived by dividing cardiac output by heart rate.
Induction of global ischaemia and re-perfusion: Total ischaemia was initiated by clamping the left atrium and the aortic perfusion tubes and reducing coronary flow to zero for 30 minutes. The hearts were then re-perfused at 37°C in working heart mode and recovery of ventricular function was followed for 30 minutes.
To investigate the action of Compound (I), this agent was added to the perfusate 15-min prior to the induction of ischaemia and then maintained throughout the re-perfusion phase.
Data Handling & Analysis: The data are presented as the mean ± SEM. Statistical significance of differences was determined using Student's t-test. Differences with p<0.05 were considered to be statistically significant.
Results: Baseline functional parameters for perfused normal male Wistar rat hearts ex vivo are shown in Table 1. In the perfusion system used here, at a constant outflow resistance, aortic flow reflects ventricular contractility [16]. The effects on cardiac function of inclusion of Compound (I) (1 uM) in the perfusate 15 min prior to zero-flow ischaemia (30 min) and subsequent re-perfusion, are shown in
Figure 1. The data demonstrate that recovery of post-ischaemic control hearts is relatively slow and not all functional parameters (e.g. cardiac output) return to pre-ischaemic levels, even after 30 min re-perfusion. Inclusion of Compound (I) in the perfusate prior to ischaemia significantly enhanced the rate of recovery of each of the functional indices. For example, inclusion of Compound (I) (1 μM) in the perfusate for 15 min prior to, during ischaemia and during the subsequent re-perfusion phase, enhanced the recovery in cardiac output and heart rate.
Conclusions The results of this study suggest that Compound (I) possesses protective properties of rapid onset in both normal and diabetic rat hearts subjected to zero-flow ischaemia in vitro.
References 1. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., Wilkison, W.O., Wilison, T.M. & Kliewer, S.A. 1995. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor gamma (PPAR gamma). J. Biol. Chem., 270 (22), 12953-12956.
2. Berger, J.. Bailey, P., Biswas, C, Cullinan, C.A., Doebber, T.W., Hayes, N.S.,
Saperstein, R., Smith, R.G. & Leibowitz, M.D. 1996. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology, 137 (10), 4189-4195.
3. Young, P.W., Buckle. D.R., Cantello, B.C.C., Chapman, H., Clapham. J.C, Coyle, P.J., Haigh, D., Hindley, R.M., Holder, J.C, Kallender, H., Latter, A.J., Lawrie, K.W.M., Mossakowska, D., Murphy, G.J., Cox, L.R. & Smith, S.A. 1998. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL 49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J. Pharmacol. Exp. Ther., 284,
751-759.
4. Zhang, F., Sowers, J.R., Ram, J.L., Standley, P.R. & Peuler, J.D. 1994. Effects of pioglitazone on calcium channels in vascular smooth muscle. Hypertension, 24, 170- 175.
5. Song, J., Walsh, M.F., Igwe, R., Ram, J.L., Barazi, M., Dominguez, L.J. & Sowers, J.R. 1997. Troglitazone reduces contraction by inhibiton of vascular smooth muscle cell Ca 2+ currents and not endothelial nitric oxide production. Diabetes, 46, 659-664.
6. Nakamura, Y., Ohya, Y., Onaka, U., Fujii, K., Abe, I. & Fujishima, M. 1998.
Inhibitory action of insulin-sensitizing agents on calcium channels in smooth muscle cells from resistance arteries of guinea-pig. Br. J. Pharmac, 123, 675-682.
7. BRL-049653/RSD-100T6C/1. Differential effects of insulin-sensitizing agents troglitazone and rosiglitazone (BRL 49653) on Ca 2+ and K+ currents in rat vascular smooth muscle cells. Knock, G.A., Mishra, S.K. & Aaronson, P.I.. June 1998.
8. Lee, K. & Boden, P. 1997. Troglitazone inhibits type 2 K ATP channel activity and depolarises tolbutamide-sensitive neurones in the rat ventromedial hypothalamus.
Brain Research, 751, 165-168. 9. Ciaraldi, T.P.. Gilmore, A., Olefsky, J.M., Goldberg, M. & Heidenreich, K.A. 1990. In vitro studies on the action of CS-045, a new antidiabetic agent. Metabolism, 39, 1056- 1062.
10. Murano, K., Inoue, Y., Emoto, M., Kaku, K. & Kaneko, T. 1994. CS-045, a new antidiabetic agent, stimulates fructose-2,6-bisphosphate production in rat hepatocytes.
Eur. J. Pharmacol, 254, 257-262.
11. Kellerer, M., Kroder, G., Tippmer, S., Berti, L., Kiehn, R., Mosthaf, L. & Haring, H. 1994. troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts. Diabetes, 43, 447-453.
12. Bahr, M., Spelleken, M., Bock, M., Von Holtey, M., Kiehn, R. & Eckel, J.. 1996. Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes. Diabetologia, 39, 766-774.
13. Eckel, J., Muller, H., Niggeman, J., Fujiwara, T., Horikoshi, H., Kiehn, R.. 1997. Troglitazone-induced insulin-sensitizing in cardiac muscle of diabetic ZDF-rats correlates to inhibition and redistribution of membrane-associated PKC Diabetes, 46
(suppl), 149A, 0575.
14. Ren, J., Dominguez, L.J., Sowers, J.R. & Davidoff, A.J. 1996. Troglitazone attenuates high-glucose-induced abnormalities in relaxation and intracellular calcium in rat ventricular myocytes. Diabetes, 45, 1822-1825.
15. Shimabukuro, M., Higa, S., Shinzato, T., Nagamine, F., Komiya, I. & Takasu, N.
1996. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism, 45, 1168-1173.
16. Neely, J.R., Liebermeister, H., Battersby, E.J. & Morgan, H.E.. 1967. Effect of pressure development on oxygen consumption by isolated rat heart. Am. J. Physiol, 212, 804-814.
17. Garber, D.W. & Neely, J.R. 1983. Decreased myocardial function and myosin ATPase in hearts from diabetic rats. Am. J. Physiol, 244, H586-H591.
18. Khandoudi, N., Bernard, M., Cozzone, P. & Feuvray, D. 1990. Intracellular pH and role of Na+/H+ exchange during ischaemia and reperfusion of normal and diabetic rat hearts. Cardiovasc. Res., 24, 873-878. Tables and Figures
Table 1
Figure imgf000016_0001
Table 2
Figure imgf000017_0001

Claims

CLAIMS:
1. A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
2. A method according to claim 1, wherein the glucose uptake enhancer is a thiazolidinedione.
3. A method according to claim 2, wherein the thiazolidinedione is Compound (I), or the tautomeric form thereof, or a pharmaceutically acceptable derivative thereof.
4. A method according to claim 3, wherein the thiazolidinedione is selected from: (+) -5-[[4-[(3,4-dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-l- benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(l -methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5- ylmethyl)thiazolidine-2,4-dione (or englitazone); or a pharmaceutically acceptable derivative thereof.
5. A pharmaceutical composition comprising a glucose uptake enhancer, and a pharmaceutically acceptable carrier, wherein such composition is adapted for acute administration.
PCT/GB1999/002358 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart WO2000004889A1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
APAP/P/2001/002033A AP1416A (en) 1998-07-21 1999-07-21 Uses of glucose uptake enhancer for reducing post-ischmemic injury of the heart.
SK102-2001A SK1022001A3 (en) 1998-07-21 1999-07-21 USE OF GLUCOSE UPTAKE ENHANCER FOR REDUCING POST-ISCHEMIC INJURYì (54) OF THE HEART
DE69930125T DE69930125T2 (en) 1998-07-21 1999-07-21 Use of an enhancer of glucose uptake to reduce postischemic cardiac damage
PL99345663A PL345663A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
AU50535/99A AU5053599A (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
SI9930889T SI1098638T1 (en) 1998-07-21 1999-07-21 Use of a glucose uptake enhancer for reducing post-ischemic injury of the heart
EP99934911A EP1098638B1 (en) 1998-07-21 1999-07-21 Use of a glucose uptake enhancer for reducing post-ischemic injury of the heart
BR9912144-1A BR9912144A (en) 1998-07-21 1999-07-21 Use of glucose absorption as a promoter to reduce post-ischemic heart damage
NZ509175A NZ509175A (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post- ischemic injury of the heart
EA200100164A EA004772B1 (en) 1998-07-21 1999-07-21 Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione for reducing post-ischemic injury of the heart
CA002338216A CA2338216A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
KR1020017000924A KR20010079550A (en) 1998-07-21 1999-07-21 Use Of Glucose Uptake Enhancer for Reducing Post-ischemic Injury of the Heart
IL14074199A IL140741A0 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
JP2000560882A JP2002521325A (en) 1998-07-21 1999-07-21 Use of a glucose uptake enhancer to reduce cardiac damage after ischemia
NO20010293A NO20010293L (en) 1998-07-21 2001-01-18 Use of glucose uptake enhancer to reduce post-ischemic heart damage
BG105251A BG105251A (en) 1998-07-21 2001-02-14 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
CY20061100616T CY1106078T1 (en) 1998-07-21 2006-05-12 USE OF GLUCOSE UPTAKE ENHANCER TO REDUCE POST-ISCHEMIC HEART DAMAGE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GB9815872.8 1999-03-09
GB9815871.0 1999-03-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09744118 A-371-Of-International 2001-01-19
US10/348,456 Continuation US6613785B2 (en) 1998-07-21 2003-01-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart

Publications (1)

Publication Number Publication Date
WO2000004889A1 true WO2000004889A1 (en) 2000-02-03

Family

ID=26314086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/002358 WO2000004889A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing post-ischemic injury of the heart

Country Status (35)

Country Link
EP (2) EP1523980A3 (en)
JP (1) JP2002521325A (en)
KR (1) KR20010079550A (en)
CN (1) CN1167416C (en)
AP (1) AP1416A (en)
AR (1) AR020614A1 (en)
AT (1) ATE318588T1 (en)
AU (1) AU5053599A (en)
BG (1) BG105251A (en)
BR (1) BR9912144A (en)
CA (1) CA2338216A1 (en)
CO (1) CO5060465A1 (en)
CY (1) CY1106078T1 (en)
CZ (1) CZ2001250A3 (en)
DE (1) DE69930125T2 (en)
DK (1) DK1098638T3 (en)
DZ (1) DZ2854A1 (en)
EA (1) EA004772B1 (en)
ES (1) ES2259839T3 (en)
GC (1) GC0000173A (en)
HU (1) HUP0103870A3 (en)
ID (1) ID27850A (en)
IL (1) IL140741A0 (en)
MA (1) MA26662A1 (en)
NO (1) NO20010293L (en)
NZ (1) NZ509175A (en)
OA (1) OA11583A (en)
PE (1) PE20000881A1 (en)
PL (1) PL345663A1 (en)
PT (1) PT1098638E (en)
SI (1) SI1098638T1 (en)
SK (1) SK1022001A3 (en)
TR (1) TR200100208T2 (en)
TW (2) TWI239836B (en)
WO (1) WO2000004889A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095906A1 (en) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Treatment and prevention of cardiac insulin resistance associated conditions
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
US7629375B2 (en) 2001-07-23 2009-12-08 Johnson & Johnson Consumer Companies, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (en) * 1992-01-24 1993-08-10 Sankyo Co Ltd Therapeutic agent for diabetic complication
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1997046238A1 (en) * 1996-06-07 1997-12-11 Glaxo Group Limited Medicaments for ameliorating endothelial cell activation
WO1998008531A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of glp-1 or analogs in treatment of myocardial infarction
WO1998010760A1 (en) * 1996-09-12 1998-03-19 Sankyo Company, Limited Glutathione reductase activity potentiator containing troglitazone
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228A1 (en) * 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (en) * 1992-01-24 1993-08-10 Sankyo Co Ltd Therapeutic agent for diabetic complication
WO1994005659A1 (en) * 1992-09-05 1994-03-17 Smithkline Beecham Plc Substituted thiazolidinedione derivatives
WO1997046238A1 (en) * 1996-06-07 1997-12-11 Glaxo Group Limited Medicaments for ameliorating endothelial cell activation
WO1998008531A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of glp-1 or analogs in treatment of myocardial infarction
WO1998010760A1 (en) * 1996-09-12 1998-03-19 Sankyo Company, Limited Glutathione reductase activity potentiator containing troglitazone
WO1999025346A1 (en) * 1997-11-19 1999-05-27 Takeda Chemical Industries, Ltd. Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BAHR M ET AL: "Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes.", DIABETOLOGIA, (1996 JUL) 39 (7) 766-74., XP000856911 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HORIKOSHI, HIROYOSHI ET AL: "Thiazolidines for treatment of complications of diabetes", XP002124805, retrieved from STN Database accession no. 119:262523 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YOKOYAMA, TOMIHISA ET AL: "Glutathione reductase activity potentiator containing troglitazone", XP002124804, retrieved from STN Database accession no. 128:248588 *
SHIMABUKURO M ET AL: "Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats.", METABOLISM: CLINICAL AND EXPERIMENTAL, (1996 SEP) 45 (9) 1168-73., XP000856580 *
STERNON J: "[Post myocardial infarction management]. La prise en charge du post-infarctus.", REVUE MEDICALE DE BRUXELLES, (1997 SEP) 18 (4) 286-92. REF: 28, XP000856587 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
US6610696B2 (en) 1999-08-27 2003-08-26 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors
US6825222B2 (en) 1999-08-27 2004-11-30 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors
WO2001095906A1 (en) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Treatment and prevention of cardiac insulin resistance associated conditions
US7629375B2 (en) 2001-07-23 2009-12-08 Johnson & Johnson Consumer Companies, Inc. Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods

Also Published As

Publication number Publication date
BG105251A (en) 2001-10-31
NO20010293D0 (en) 2001-01-18
EA200100164A1 (en) 2001-08-27
KR20010079550A (en) 2001-08-22
EA004772B1 (en) 2004-08-26
DE69930125D1 (en) 2006-04-27
NO20010293L (en) 2001-03-07
SI1098638T1 (en) 2006-06-30
EP1523980A2 (en) 2005-04-20
EP1523980A3 (en) 2009-03-18
CY1106078T1 (en) 2011-06-08
AP1416A (en) 2005-06-13
NZ509175A (en) 2003-10-31
TW200307532A (en) 2003-12-16
ID27850A (en) 2001-04-26
MA26662A1 (en) 2004-12-20
CZ2001250A3 (en) 2002-03-13
CN1167416C (en) 2004-09-22
CA2338216A1 (en) 2000-02-03
BR9912144A (en) 2001-04-03
AR020614A1 (en) 2002-05-22
AU5053599A (en) 2000-02-14
TWI239836B (en) 2005-09-21
OA11583A (en) 2004-07-01
HUP0103870A2 (en) 2002-05-29
HUP0103870A3 (en) 2003-06-30
EP1098638A1 (en) 2001-05-16
ATE318588T1 (en) 2006-03-15
CN1310619A (en) 2001-08-29
TR200100208T2 (en) 2001-05-21
AP2001002033A0 (en) 2001-03-31
EP1098638B1 (en) 2006-03-01
GC0000173A (en) 2006-03-29
JP2002521325A (en) 2002-07-16
IL140741A0 (en) 2002-02-10
SK1022001A3 (en) 2001-08-06
PL345663A1 (en) 2002-01-02
DZ2854A1 (en) 2003-12-01
PT1098638E (en) 2006-07-31
ES2259839T3 (en) 2006-10-16
DE69930125T2 (en) 2006-10-05
DK1098638T3 (en) 2006-06-19
CO5060465A1 (en) 2001-07-30
PE20000881A1 (en) 2000-10-07

Similar Documents

Publication Publication Date Title
US6699889B2 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
NO324993B1 (en) Combination of 5- [4- [2- (N-methyl-N- (2-pyridyl) amino) -ethoxy] benzyl] thiazolidine-2,4-dione and metformin and their use and pharmaceutical composition.
EP1098638B1 (en) Use of a glucose uptake enhancer for reducing post-ischemic injury of the heart
EP1098639B1 (en) Use of the glucose uptake enhancer rosiglitazone for reducing ischaemia-induced apoptosis of pancreatic beta cells, endothelial cells and neuronal cells
US20020099082A1 (en) Use of glucose uptake enhancer for reducing apoptosis
AU2005202209A1 (en) Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
ZA200100439B (en) Use of glucose uptake enhancer for reducing postischemic injury of the heart.
AU2768402A (en) Use of glucose uptake enhancer for reducing apoptosis
US20040192737A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
US20010031776A1 (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
CZ20001298A3 (en) Medicament for treating hyperglycemia and pharmaceutical preparation containing insulin sensitizer
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99808982.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1999934911

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 509175

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/00034/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 50535/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001/00439

Country of ref document: ZA

Ref document number: 200100439

Country of ref document: ZA

Ref document number: 1200100051

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 2001/00208

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2338216

Country of ref document: CA

Ref document number: 2000 560882

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2338216

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1022001

Country of ref document: SK

Ref document number: PA/a/2001/000734

Country of ref document: MX

Ref document number: PV2001-250

Country of ref document: CZ

Ref document number: 09744118

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1020017000924

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1999 105251

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200100164

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999934911

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017000924

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-250

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1999934911

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1020017000924

Country of ref document: KR